spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  selective androgen receptor modulator 

 HSMN NewsFeed - 12 Jul 2017
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Biopharmaceuticals Orthopaedic
 HSMN NewsFeed - 6 Jul 2017
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2017
FDA Approves Radius Health’s TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jan 2017
Viking Therapeutics Announces Senior Level Appointments to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2016
OPKO Health to Acquire Transition Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Nov 2015
Hi-Tech Pharmaceuticals Files Lawsuit Against IronMag Labs and Robert Dimaggio Over Racketeer Influenced and Corrupt Organizations (RICO) and Patent Infringement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 13 Oct 2015
GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 8 Jul 2015
GTx Appoints Diane Young, M.D. as Vice President, Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Apr 2009
First Ever Prospective Fracture Study in Prostate Cancer Patients on ADT Reveals These Men Are at High Risk for Skeletal Fractures
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 20 Nov 2008
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 May 2008
GTx Appoints Kenneth S. Robinson, MD to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Mar 2008
GTx Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2007
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jul 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2007
GTx Announces Ostarine(TM) Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Apr 2007
GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2007
GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2007
GTx's ACAPODENE Interim Bone Mineral Density and Lipid Data Highlighted at Press Briefing at Prostate Cancer Symposium of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
GTx Announces That Ostarine Achieved Primary Endpoint of Lean Body Mass and a Secondary Endpoint of Improved Functional Performance in a Phase II Clinical Trial and Reacquisition of Full Rights to GTx SARM Program
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2006
GTx and Ipsen Enter Into Partnership Agreement for the European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Sep 2006
Ipsen and GTx Enter into Partnership Agreement for The European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 Jun 2006
In a Phase III Lipid Interim Analysis, ACAPODENE Treatment Lowered Cholesterol and Raised HDL In Prostate Cancer Patients On Androgen Deprivation Therapy
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
selective androgen receptor modulator
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.